Hyunsoo Ellis
Family · Los Angeles, CANPI 1801561220
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,131 and has fallen 89.4% since, to $227 in 2025.
Across 158 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$509
- Lilly USA, LLC$246
- Optinose US, Inc.$244
- Sanofi-aventis U.S. LLC$177
- Amgen$168
- AstraZeneca$152
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,696100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $509 |
| Lilly USA, LLC | 17 | $246 |
| Optinose US, Inc. | 16 | $244 |
| Sanofi-aventis U.S. LLC | 10 | $177 |
| Amgen | 11 | $168 |
| AstraZeneca | 11 | $152 |
| Novo Nordisk | 11 | $147 |
| Kowa Pharmaceuticals America, Inc. | 1 | $120 |
| Vivus LLC | 7 | $120 |
| Scilex Pharmaceuticals Inc. | 5 | $111 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $101 |
| Novartis | 6 | $85 |
| Amarin Pharma, Inc. | 4 | $84 |
| Boehringer Ingelheim | 4 | $61 |
| Bayer | 2 | $53 |
| IBSA Pharma Inc. | 3 | $52 |
| Dexcom, Inc. | 3 | $48 |
| GSK | 3 | $37 |
| Organon | 1 | $33 |
| Ardelyx, Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Seglentis$120
How this compares
$2,696 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 16 | $170 |
| Metformin Hcl | 18 | $131 |
Paid to pharmacies, not to this prescriber.
Other family in Los Angeles
- Annette ShonLos Angeles$406K
- Phyllis CasonLos Angeles$187K
- Theodore SolomonLos Angeles$131K
- Angela SarffLos Angeles$51K
- Karla MenjivarLos Angeles$36K
- Janet GripshoverLos Angeles$30K
- Jualynda SmithLos Angeles$28K
- Phoebedel ReyesLos Angeles$26K
- Ayana ElliottLos Angeles$25K
- Lori RobertsonChino Hills$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.